Global Targeted-protein Degradation Therapeutics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Targeted-protein Degradation Therapeutics market size will reach US$ 2014 million by 2031.
Targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway.
The Protein Degradation Therapy market has gained momentum as a promising approach in drug development. This innovative strategy aims to target disease-causing proteins by facilitating their degradation within cells. Proteins that contribute to diseases like cancer and neurodegenerative disorders can be selectively broken down using small molecules known as proteolysis-targeting chimeras (PROTACs) or other protein degraders. This approach offers advantages over traditional inhibition methods, potentially leading to more effective treatments with reduced side effects. As researchers delve into protein-protein interactions and cellular mechanisms, the Protein Degradation Therapy market is expanding, presenting opportunities to address previously challenging diseases and advance precision medicine. Clinical progress and continued research in this field are expected to shape the future of therapeutic interventions.
LPI (LP Information)' newest research report, the “Targeted-protein Degradation Therapeutics Industry Forecast” looks at past sales and reviews total world Targeted-protein Degradation Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted-protein Degradation Therapeutics sales for 2025 through 2031. With Targeted-protein Degradation Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted-protein Degradation Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Targeted-protein Degradation Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted-protein Degradation Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted-protein Degradation Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted-protein Degradation Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted-protein Degradation Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted-protein Degradation Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
ARV-110
ARV-471
Other
Segmentation by Application:
Cancer
Neuroscience
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arvinas
Nurix Therapeutics
Kymera Therapeutics
C4 Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway.
The Protein Degradation Therapy market has gained momentum as a promising approach in drug development. This innovative strategy aims to target disease-causing proteins by facilitating their degradation within cells. Proteins that contribute to diseases like cancer and neurodegenerative disorders can be selectively broken down using small molecules known as proteolysis-targeting chimeras (PROTACs) or other protein degraders. This approach offers advantages over traditional inhibition methods, potentially leading to more effective treatments with reduced side effects. As researchers delve into protein-protein interactions and cellular mechanisms, the Protein Degradation Therapy market is expanding, presenting opportunities to address previously challenging diseases and advance precision medicine. Clinical progress and continued research in this field are expected to shape the future of therapeutic interventions.
LPI (LP Information)' newest research report, the “Targeted-protein Degradation Therapeutics Industry Forecast” looks at past sales and reviews total world Targeted-protein Degradation Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted-protein Degradation Therapeutics sales for 2025 through 2031. With Targeted-protein Degradation Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted-protein Degradation Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Targeted-protein Degradation Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted-protein Degradation Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted-protein Degradation Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted-protein Degradation Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted-protein Degradation Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted-protein Degradation Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
ARV-110
ARV-471
Other
Segmentation by Application:
Cancer
Neuroscience
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arvinas
Nurix Therapeutics
Kymera Therapeutics
C4 Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
73 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Targeted-protein Degradation Therapeutics Market Size by Player
- 4 Targeted-protein Degradation Therapeutics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Targeted-protein Degradation Therapeutics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
